{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:20:48Z","timestamp":1747207248983,"version":"3.40.5"},"reference-count":80,"publisher":"Bentham Science Publishers Ltd.","issue":"16","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":393,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The review is devoted to the development and study of the drug Leukovir\u00ae (cladribine+\nribavirin) and its use in the treatment of relapsing-remitting and secondary progressive\nforms of multiple sclerosis, a chronic neurodegenerative disease aiming the risk reduction of relapse\nand progression of a disability. In clinical trials Leukovir\u00ae has proved to be efficient by up to\n56 weeks for the treatment of relapsing-remitting and secondary progressive forms of multiple\nsclerosis. The drug is registered in the Republic of Belarus. The efficacy, safety and tolerability\nprofile of the drug Leukovir\u00ae suggests that it is well suited for disease-modifying therapy of multiple\nsclerosis. Patients require four 35-day courses of treatment, each consisting of seven days of\ntreatment followed by a break of 28 days. The use of Leukovir\u00ae has contributed to the suppression\nof inflammatory process activity according to MRI data and stabilization of the clinical condition.\nIt has reduced the number of relapses in patients with relapsing-remitting and secondary-progressive\nforms of multiple sclerosis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113894501272301231124074141","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T11:12:48Z","timestamp":1701429168000},"page":"1271-1281","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Development of the Combination Drug Leukovir\u00ae Tablets for the\nTreatment of Multiple Sclerosis: A Comprehensive Review"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9138-9271","authenticated-orcid":true,"given":"Elena N.","family":"Kalinichenko","sequence":"first","affiliation":[{"name":"Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, BY-220141, 5\/2 Academician V.F. Kuprevich Street, Minsk, Belarus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana V.","family":"Babitskaya","sequence":"additional","affiliation":[{"name":"Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, BY-220141, 5\/2 Academician V.F. Kuprevich\nStreet, Minsk, Belarus"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"Compston A.","year":"2008","unstructured":"Compston A.; Coles A.; Multiple sclerosis. Lancet  2008,372(9648),1502-1517","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","DOI":"10.15586\/codon.multiplesclerosis.2017.ch1","author":"Didonna A.","year":"2017","unstructured":"Didonna A.; Oksenberg J.R.; The genetics of multiple sclerosis. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis  2017","journal-title":"Multiple Sclerosis: Perspectives in Treatment and Pathogenesis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00281-021-00907-3","volume":"44","author":"Kim W.","year":"2022","unstructured":"Kim W.; Patsopoulos N.A.; Genetics and functional genomics of multiple sclerosis. Semin Immunopathol  2022,44(1),63-79","journal-title":"Semin Immunopathol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"McGinley M.P.","year":"2021","unstructured":"McGinley M.P.; Goldschmidt C.H.; Rae-Grant A.D.; Diagnosis and treatment of multiple sclerosis. JAMA  2021,325(8),765-779","journal-title":"JAMA"},{"key":"ref=5","author":"Cree B.A.C.","year":"2007","unstructured":"Cree B.A.C.; Multiple sclerosis. Current Diagnosis and Treatment in Neurology  2007","journal-title":"Current Diagnosis and Treatment in Neurology"},{"key":"ref=6","first-page":"175","volume":"37","author":"Goldenberg M.M.","year":"2012","unstructured":"Goldenberg M.M.; Multiple sclerosis review. PandT  2012,37(3),175-184","journal-title":"PandT"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/brainsci13071009","volume":"13","author":"Al Johani K","year":"2023","unstructured":"Al Johani K; Fudah M; Al-Zahrani M; Multiple sclerosis-a demyelinating disorder and its dental considerations-a literature review with own case report. Brain Sci  2023,13(7),1009","journal-title":"Brain Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s11481-020-09948-1","volume":"16","author":"Wang Z.","year":"2021","unstructured":"Wang Z.; Kennedy P.G.E.; Dupree C.; Wang M.; Lee C.; Pointon T.; Langford T.D.; Graner M.W.; Yu X.; Antibodies from multiple sclerosis brain identified epstein-barr virus nuclear antigen 1 and 2 epitopes which are recognized by oligoclonal bands. J Neuroimmune Pharmacol  2021,16(3),567-580","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"796378","DOI":"10.3389\/fneur.2021.796378","volume":"12","author":"Pachner A.R.","year":"2022","unstructured":"Pachner A.R.; The neuroimmunology of multiple sclerosis: Fictions and facts. Front Neurol  2022,12,796378","journal-title":"Front Neurol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","volume":"31","author":"Trapp B.D.","year":"2008","unstructured":"Trapp B.D.; Nave K.A.; Multiple sclerosis: An immune or neurodegenerative disorder? Annu Rev Neurosci  2008,31(1),247-269","journal-title":"Annu Rev Neurosci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1352458517737371","volume":"24","author":"Cant\u00f3 E.","year":"2018","unstructured":"Cant\u00f3 E.; Oksenberg J.R.; Multiple sclerosis genetics. Mult Scler  2018,24(1),75-79","journal-title":"Mult Scler"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2217\/fvl.12.78","volume":"7","author":"Delbue S.","year":"2012","unstructured":"Delbue S.; Carluccio S.; Ferrante P.; The long and evolving relationship between viruses and multiple sclerosis. Future Virol  2012,7(9),871-883","journal-title":"Future Virol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"528","DOI":"10.2174\/187152712801661220","volume":"11","author":"Oskari Virtanen J.","year":"2012","unstructured":"Oskari Virtanen J.; Jacobson S.; Viruses and multiple sclerosis. CNS Neurol Disord Drug Targets  2012,11(5),528-544","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1177\/1352458510394397","volume":"17","author":"Oikonen M.","year":"2011","unstructured":"Oikonen M.; Laaksonen M.; Aalto V.; Ilonen J.; Salonen R.; Er\u00e4linna J.P.; Panelius M.; Salmi A.; Temporal relationship between environmental influenza A and Epstein\u2013Barr viral infections and high multiple sclerosis relapse occurrence. Mult Scler  2011,17(6),672-680","journal-title":"Mult Scler"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1191\/1352458505ms1185oa","volume":"11","author":"Friedman J.E.","year":"2005","unstructured":"Friedman J.E.; Zabriskie J.B.; Plank C.; Ablashi D.; Whitman J.; Shahan B.; Edgell R.; Shieh M.; Rapalino O.; Zimmerman R.; Sheng D.; A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler  2005,11(3),286-295","journal-title":"Mult Scler"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41582-023-00775-5","volume":"19","author":"Bjornevik K.","year":"2023","unstructured":"Bjornevik K.; M\u00fcnz C.; Cohen J.I.; Ascherio A.; Epstein\u2013Barr virus as a leading cause of multiple sclerosis: Mechanisms and implications. Nat Rev Neurol  2023,19(3),160-171","journal-title":"Nat Rev Neurol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13073-019-0640-z","volume":"11","author":"Afrasiabi A.","year":"2019","unstructured":"Afrasiabi A.; Parnell G.P.; Fewings N.; Schibeci S.D.; Basuki M.A.; Chandramohan R.; Zhou Y.; Taylor B.; Brown D.A.; Swaminathan S.; McKay F.C.; Stewart G.J.; Booth D.R.; Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility. Genome Med  2019,11(1),26","journal-title":"Genome Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/ane.12775","volume":"136","author":"Mentis A.F.A.","year":"2017","unstructured":"Mentis A.F.A.; Dardiotis E.; Grigoriadis N.; Petinaki E.; Hadjigeorgiou G.M.; Viruses and endogenous retroviruses in multiple sclerosis: From correlation to causation. Acta Neurol Scand  2017,136(6),606-616","journal-title":"Acta Neurol Scand"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00284-022-03112-z","volume":"80","author":"Sedighi S.","year":"2023","unstructured":"Sedighi S.; Gholizadeh O.; Yasamineh S.; Akbarzadeh S.; Amini P.; Favakehi P.; Afkhami H.; Firouzi-Amandi A.; Pahlevan D.; Eslami M.; Yousefi B.; Poortahmasebi V.; Dadashpour M.; Comprehensive investigations relationship between viral infections and multiple sclerosis pathogenesis. Curr Microbiol  2023,80(1),15","journal-title":"Curr Microbiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1007\/s00415-020-10265-z","volume":"268","author":"Kennedy P.G.E.","year":"2021","unstructured":"Kennedy P.G.E.; An overview of viral infections of the nervous system in the immunosuppressed. J Neurol  2021,268(8),3026-3030","journal-title":"J Neurol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s11882-023-01102-0","volume":"23","author":"Vasileiou E.S.","year":"2023","unstructured":"Vasileiou E.S.; Fitzgerald K.C.; Multiple sclerosis pathogenesis and updates in targeted therapeutic approaches. Curr Allergy Asthma Rep  2023,23(9),481-496","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1503\/cmaj.130727","volume":"186","author":"Tavazzi E.","year":"2014","unstructured":"Tavazzi E.; Rovaris M.; La Mantia L.; Drug therapy for multiple sclerosis. CMAJ  2014,186(11),833-840","journal-title":"CMAJ"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/00003495-200059030-00002","volume":"59","author":"Weinstock-Guttman B.","year":"2000","unstructured":"Weinstock-Guttman B.; Jacobs L.D.; What is new in the treatment of multiple sclerosis? Drugs  2000,59(3),401-410","journal-title":"Drugs"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jim-2016-000339","volume":"65","author":"Vargas D.L.","year":"2017","unstructured":"Vargas D.L.; Tyor W.R.; Update on disease-modifying therapies for multiple sclerosis. J Investig Med  2017,65(5),883-891","journal-title":"J Investig Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1471-2377-12-95","volume":"12","author":"Oreja-Guevara C.","year":"2012","unstructured":"Oreja-Guevara C.; Ramos-Cejudo J.; Aroeira L.S.; Chamorro B.; Diez-Tejedor E.; TH1\/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. BMC Neurol  2012,12(1),95","journal-title":"BMC Neurol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.nurt.2007.07.008","volume":"4","author":"Frohman E.M.","year":"2007","unstructured":"Frohman E.M.; Shah A.; Eggenberger E.; Metz L.; Zivadinov R.; St\u00fcve O.; Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics  2007,4(4),618-626","journal-title":"Neurotherapeutics"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1600-0404.2009.01213.x","volume":"120","author":"Myhr K.M.","year":"2009","unstructured":"Myhr K.M.; Mellgren S.I.; Corticosteroids in the treatment of multiple sclerosis. Acta Neurol Scand  2009,120(189),73-80","journal-title":"Acta Neurol Scand"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"108401","DOI":"10.1016\/j.steroids.2019.04.006","volume":"149","author":"Saied A.","year":"2019","unstructured":"Saied A.; Elsaid N.; Azab A.; Long term effects of corticosteroids in multiple sclerosis in terms of the \u201cno evidence of disease activity\u201d (NEDA) domains. Steroids  2019,149,108401","journal-title":"Steroids"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1177\/1352458509106937","volume":"15","author":"Montalban X.","year":"2009","unstructured":"Montalban X.; Sastre-Garriga J.; Tintor\u00e9 M.; Brieva L.; Aymerich F.X.; R\u00edo J.; Porcel J.; Borr\u00e0s C.; Nos C.; Rovira \u00c0.; A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler  2009,15(10),1195-1205","journal-title":"Mult Scler"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1007\/s10072-021-05052-1","volume":"42","author":"G\u00f3mez-Figueroa E.","year":"2021","unstructured":"G\u00f3mez-Figueroa E.; Gutierrez-Lanz E.; Alvarado-Bola\u00f1os A.; Casallas-Vanegas A.; Garcia-Estrada C.; Zabala-Angeles I.; Cadena-Fernandez A.; Veronica R.A.; Irene T.F.; Flores-Rivera J.; Cyclophosphamide treatment in active multiple sclerosis. Neurol Sci  2021,42(9),3775-3780","journal-title":"Neurol Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/ana.410270603","volume":"27","author":"Wolinsky J.S.","year":"1990","unstructured":"Wolinsky J.S.; Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol  1990,27(6),591-605","journal-title":"Ann Neurol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/DNND.S161450","volume":"8","author":"Boyko A.","year":"2018","unstructured":"Boyko A.; Boyko O.; Cladribine tablets\u2019 potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degener Neurol Neuromuscul Dis  2018,8,35-44","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00011-018-1185-0","volume":"68","author":"Gholamzad M.","year":"2019","unstructured":"Gholamzad M.; Ebtekar M.; Ardestani M.S.; Azimi M.; Mahmodi Z.; Mousavi M.J.; Aslani S.; A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflamm Res  2019,68(1),25-38","journal-title":"Inflamm Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.17116\/jnevro2020120081148","volume":"120","author":"Zhuravleva M.V.","year":"2020","unstructured":"Zhuravleva M.V.; Davydovskaya M.V.; Luchinina E.V.; Shelekhova T.V.; Kurguzova D.O.; Serebrova S.Y.; Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova  2020,120(8),148-153","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00228-018-2429-1","volume":"74","author":"Eriksson I.","year":"2018","unstructured":"Eriksson I.; Komen J.; Piehl F.; Malmstr\u00f6m R.E.; Wettermark B.; von Euler M.; The changing multiple sclerosis treatment landscape: Impact of new drugs and treatment recommendations. Eur J Clin Pharmacol  2018,74(5),663-670","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2147\/TCRM.S282390","volume":"17","author":"Mancinelli C.R.","year":"2021","unstructured":"Mancinelli C.R.; De Rossi N.; Capra R.; Ocrelizumab for the treatment of multiple sclerosis: Safety, efficacy, and pharmacology. Ther Clin Risk Manag  2021,17,765-776","journal-title":"Ther Clin Risk Manag"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"104184","DOI":"10.1016\/j.msard.2022.104184","volume":"67","author":"Platzbecker K.","year":"2022","unstructured":"Platzbecker K.; Wentzell N.; Kollhorst B.; Haug U.; Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: Description of drug utilization and exposed pregnancies in Germany. Mult Scler Relat Disord  2022,67,104184","journal-title":"Mult Scler Relat Disord"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2217\/epi-2021-0296","volume":"13","author":"Azari H.","year":"2021","unstructured":"Azari H.; Karimi E.; Shekari M.; Tahmasebi A.; Nikpoor A.R.; Negahi A.A.; Sanadgol N.; Mousavi P.; Construction of a lncRNA\u2013miRNA\u2013mRNA network to determine the key regulators of the Th1\/Th2 imbalance in multiple sclerosis. Epigenomics  2021,13(22),1797-1815","journal-title":"Epigenomics"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/pharmaceutics15030728","volume":"15","author":"Ma X.","year":"2023","unstructured":"Ma X.; Ma R.; Zhang M.; Qian B.; Wang B.; Yang W.; Recent progress in multiple sclerosis treatment using immune cells as targets. Pharmaceutics  2023,15(3),728","journal-title":"Pharmaceutics"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1586\/14737175.5.6.721","volume":"5","author":"Sipe J.C.","year":"2005","unstructured":"Sipe J.C.; Cladribine for multiple sclerosis: Review and current status. Expert Rev Neurother  2005,5(6),721-727","journal-title":"Expert Rev Neurother"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1136\/jnnp-2017-317411","volume":"89","author":"Jacobs B.M.","year":"2018","unstructured":"Jacobs B.M.; Ammoscato F.; Giovannoni G.; Baker D.; Schmierer K.; Cladribine: Mechanisms and mysteries in multiple sclerosis. J Neurol Neurosurg Psychiatry  2018,89(12),1266-1271","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","volume":"14","author":"Giovannoni G.","year":"2017","unstructured":"Giovannoni G.; Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics  2017,14(4),874-887","journal-title":"Neurotherapeutics"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s12026-018-9032-5","volume":"66","author":"Karussis D.","year":"2018","unstructured":"Karussis D.; Petrou P.; Immune reconstitution therapy (IRT) in multiple sclerosis: The rationale. Immunol Res  2018,66(6),642-648","journal-title":"Immunol Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"Comi G.","year":"2019","unstructured":"Comi G.; Cook S.; Giovannoni G.; Rieckmann P.; S\u00f8rensen P.S.; Vermersch P.; Galazka A.; Nolting A.; Hicking C.; Dangond F.; Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord  2019,29,168-174","journal-title":"Mult Scler Relat Disord"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","volume":"29","author":"Cook S.","year":"2019","unstructured":"Cook S.; Leist T.; Comi G.; Montalban X.; Giovannoni G.; Nolting A.; Hicking C.; Galazka A.; Sylvester E.; Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Mult Scler Relat Disord  2019,29,157-167","journal-title":"Mult Scler Relat Disord"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1007\/s40265-020-01422-9","volume":"80","author":"Rammohan K.","year":"2020","unstructured":"Rammohan K.; Coyle P.K.; Sylvester E.; Galazka A.; Dangond F.; Grosso M.; Leist T.P.; The development of cladribine tablets for the treatment of multiple sclerosis: A comprehensive review. Drugs  2020,80(18),1901-1928","journal-title":"Drugs"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","volume":"30","author":"Baker D.","year":"2019","unstructured":"Baker D.; Pryce G.; Herrod S.S.; Schmierer K.; Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord  2019,30,176-186","journal-title":"Mult Scler Relat Disord"},{"key":"ref=48","first-page":"1196","volume":"5","author":"Kalinichenko E.","year":"2020","unstructured":"Kalinichenko E.; Ponteleeva I.; Golubeva M.; Immunotropic activity of a new cladribine\/ribavirin-based composition. Ann Pharmacol Pharm  2020,5(6),1196","journal-title":"Ann Pharmacol Pharm"},{"year":"2012","author":"Kalinichenko E.N.","unstructured":"Kalinichenko E.N.; Kuzmicki B.B.; Golubeva M.B.; Immunosuppressive composition.  2012","key":"ref=49"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4236\/abc.2022.121001","volume":"12","author":"Kalinichenko E.N.","year":"2022","unstructured":"Kalinichenko E.N.; Ponteleeva I.V.; Golubeva M.B.; Pharmacokinetic study and toxicity of leukovir: A new combined drug for the treatment of multiple sclerosis. Adv Biol Chem  2022,12(1),1-15","journal-title":"Adv Biol Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s13311-016-0455-1","volume":"13","author":"Azodi S.","year":"2016","unstructured":"Azodi S.; Jacobson S.; Cytokine therapies in neurological disease. Neurotherapeutics  2016,13(3),555-561","journal-title":"Neurotherapeutics"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40262-018-0695-9","volume":"58","author":"Hermann R.","year":"2019","unstructured":"Hermann R.; Karlsson M.O.; Novakovic A.M.; Terranova N.; Fluck M.; Munafo A.; The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis. Clin Pharmacokinet  2019,58(3),283-297","journal-title":"Clin Pharmacokinet"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1365-2141.2008.07432.x","volume":"144","author":"Chtioui H.","year":"2009","unstructured":"Chtioui H.; Millius C.; L\u00e4mmle B.; Lauterburg B.H.; Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation. Br J Haematol  2009,144(1),136-137","journal-title":"Br J Haematol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jneuroim.2011.09.010","volume":"240-241","author":"Laugel B.","year":"2011","unstructured":"Laugel B.; Borlat F.; Galibert L.; Vicari A.; Weissert R.; Chvatchko Y.; Bruniquel D.; Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity. J Neuroimmunol  2011,240-241,52-57","journal-title":"J Neuroimmunol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.intimp.2013.11.027","volume":"18","author":"Kraus S.H.P.","year":"2014","unstructured":"Kraus S.H.P.; Luessi F.; Trinschek B.; Lerch S.; Hubo M.; Poisa-Beiro L.; Paterka M.; Jonuleit H.; Zipp F.; Jolivel V.; Cladribine exerts an immunomodulatory effect on human and murine dendritic cells. Int Immunopharmacol  2014,18(2),347-357","journal-title":"Int Immunopharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00210-011-0719-6","volume":"385","author":"Jensen K.","year":"2012","unstructured":"Jensen K.; Johnson L.A.A.; Jacobson P.A.; Kachler S.; Kirstein M.N.; Lamba J.; Klotz K.N.; Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol  2012,385(5),519-525","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1182\/blood-2008-02-136325","volume":"112","author":"Novitskiy S.V.","year":"2008","unstructured":"Novitskiy S.V.; Ryzhov S.; Zaynagetdinov R.; Goldstein A.E.; Huang Y.; Tikhomirov O.Y.; Blackburn M.R.; Biaggioni I.; Carbone D.P.; Feoktistov I.; Dikov M.M.; Adenosine receptors in regulation of dendritic cell differentiation and function. Blood  2008,112(5),1822-1831","journal-title":"Blood"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.3390\/cells10123488","volume":"10","author":"Fissolo N.","year":"2021","unstructured":"Fissolo N.; Calvo-Barreiro L.; Eixarch H.; Boschert U.; Espejo C.; Montalban X.; Comabella M.; Immunomodulatory effects associated with cladribine treatment. Cells  2021,10(12),3488","journal-title":"Cells"},{"key":"ref=59","first-page":"5","volume":"17","author":"Likchachev S.A.","year":"2014","unstructured":"Likchachev S.A.; Kalinichenko E.N.; Nedzved G.K.; Buniak A.; Evaluate the efficacy and safety of leykovir in the treatment of patients with multiple sclerosis. Actual Problems of Neurology and Neurosurgery  2014,17,5-15","journal-title":"Actual Problems of Neurology and Neurosurgery"},{"key":"ref=60","author":"Kalinichenko E.N.","year":"2014","unstructured":"Kalinichenko E.N.; Kuzmitsky B.B.; Likhachev S.A.; Zubbritsky S.M.; Clinical trials of the innovative drug Leikovir for the treatment of multiple sclerosis. International Scientific and Practical Conference \"Belarus Medications  2014","journal-title":"International Scientific and Practical Conference \"Belarus Medications"},{"unstructured":"Instruction for the medical use of the drug Leukovir.  Available from:  https:\/\/www.vidal.by\/poisk_preparatov\/leukovir.html","key":"ref=61"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/07328319308017836","volume":"12","author":"Mikhailopulo I.A.","year":"1993","unstructured":"Mikhailopulo I.A.; Zinchenko A.I.; Kazimierczuk Z.; Barai V.N.; Bokut S.B.; Kalinichenko E.N.; Synthesis of 2-Chloro-2\u2032-Deoxyadenosine by Microbiological Transglycosylation. Nucleosides Nucleotides  1993,12(3-4),417-422","journal-title":"Nucleosides Nucleotides"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/1522-2675(200207)85:7<1901::AID-HLCA1901>3.0.CO;2-C","volume":"85","author":"Barai V.N.","year":"2002","unstructured":"Barai V.N.; Zinchenko A.I.; Eroshevskaya L.A.; Kalinichenko E.N.; Kulak T.I.; Mikhailopulo I.A.; A universal biocatalyst for the preparation of base- and sugar-modified nucleosides via an enzymatic transglycosylation. Helv Chim Acta  2002,85(7),1901","journal-title":"Helv Chim Acta"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.32362\/2410-6593-2019-14-4-7-23","volume":"14","author":"Chudinov M.V.","year":"2019","unstructured":"Chudinov M.V.; Ribavirin and its analogs: \u0421an you teach an old dog new tricks? Fine Chemical Technologies  2019,14(4),7-23","journal-title":"Fine Chemical Technologies"},{"key":"ref=65","first-page":"13","volume":"42","author":"Tarasiuk A.","year":"1994","unstructured":"Tarasiuk A.; Skierski J.; Kazimierczuk Z.; Stability of 2-chloro-2\u2032-deoxyadenosine at various pH and temperature. Arch Immunol Ther Exp  1994,42(1),13-15","journal-title":"Arch Immunol Ther Exp"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"reviews1027","DOI":"10.1186\/gb-2002-3-10-reviews1027","volume":"3","author":"Baranzini SE","year":"2002","unstructured":"Baranzini SE; Hauser SL; Large-scale gene-expression studies and the challenge of multiple sclerosis. Genome Biol  2002,3(10),reviews1027","journal-title":"Genome Biol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/jnr.10552","volume":"72","author":"Milicevic I.","year":"2003","unstructured":"Milicevic I.; Pekovic S.; Subasic S.; Mostarica-Stojkovic M.; Stosic-Grujicic S.; Medic-Mijacevic L.; Pejanovic V.; Rakic L.; Stojiljkovic M.; Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats. J Neurosci Res  2003,72(2),268-278","journal-title":"J Neurosci Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/923614","volume":"2015","author":"Bozic I.","year":"2015","unstructured":"Bozic I.; Savic D.; Jovanovic M.; Bjelobaba I.; Laketa D.; Nedeljkovic N.; Stojiljkovic M.; Pekovic S.; Lavrnja I.; Low-dose ribavirin treatments attenuate neuroinflammatory activation of BV-2 Cells by interfering with inducible nitric oxide synthase. Anal Cell Pathol  2015,2015,1-8","journal-title":"Anal Cell Pathol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"626","DOI":"10.4161\/cbt.310","volume":"1","author":"Kast R.E.","year":"2002","unstructured":"Kast R.E.; Ribavirin in cancer immunotherapies: Controlling nitric oxide helps generate cytotoxic lymphocyte. Cancer Biol Ther  2002,1(6),626-630","journal-title":"Cancer Biol Ther"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4155\/fmc.09.147","volume":"2","author":"Braun-Sand S.B.","year":"2010","unstructured":"Braun-Sand S.B.; Peetz M.; Inosine monophosphate dehydrogenase as a target for antiviral, anticancer, antimicrobial and immunosuppressive therapeutics. Future Med Chem  2010,2(1),81-92","journal-title":"Future Med Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.coviro.2014.04.011","volume":"8","author":"Beaucourt S.","year":"2014","unstructured":"Beaucourt S.; Vignuzzi M.; Ribavirin: A drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance. Curr Opin Virol  2014,8,10-15","journal-title":"Curr Opin Virol"},{"key":"ref=72","first-page":"47","author":"Kuzmitsky B.B.","year":"2014","unstructured":"Kuzmitsky B.B.; Golubeva M.B.; Kalinichenko E.N.; Zinchenko A.; Leukovir - a rational dosage form for multiple sclerosis. Bioregulators: research and application, issue 3: collection of scientific papers  2014,47-60","journal-title":"Bioregulators: research and application, issue 3: collection of scientific papers"},{"year":"2018","author":"Kalinichenko E.N.","unstructured":"Kalinichenko E.N.; Likhachev S.A.; Bunyak A.G.; Drug Product with a Prolonged Action for the Treatment of Multiple Sclerosis (Options).  2018","key":"ref=73"},{"key":"ref=74","author":"Kalinichenko E.N.","year":"2019","unstructured":"Kalinichenko E.N.; Kuzmitsky B.B.; Likhachev S.A.; Zubbritsky S.M.; Clinical studies of the innovative drug Leucovir for the treatment of multiple sclerosis. All-Russian Scientific and Practical Conference \u201cTopical Issues in Research and Treatment of Multiple Sclerosis  2019","journal-title":"All-Russian Scientific and Practical Conference \u201cTopical Issues in Research and Treatment of Multiple Sclerosis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"Giovannoni G.","year":"2010","unstructured":"Giovannoni G.; Comi G.; Cook S.; Rammohan K.; Rieckmann P.; S\u00f8rensen P.S.; Vermersch P.; Chang P.; Hamlett A.; Musch B.; Greenberg S.J.; A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med  2010,362(5),416-426","journal-title":"N Engl J Med"},{"key":"ref=76","first-page":"111","volume":"3","author":"Zavalishin I.A.","year":"2006","unstructured":"Zavalishin I.A.; Peresedova A.V.; Sto\u012dda N.I.; Rebrova Oi.; Zakharova M.N.; Adarcheva L.S.; Niazbekova A.S.; Askarova L.Sh.; Ba\u012ddina E.V.; A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova  2006,3,111-115","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref=77","first-page":"449","volume":"74","author":"Arends R.J.","year":"2019","unstructured":"Arends R.J.; Wang D.; Buurman M.; Luten J.; Koper N.P.; Wolf C.; Scheren M.; Comparison of Copaxone and Synthon\u2019s therapeutically equivalent glatiramer acetate. Pharmazie  2019,74(8),449-461","journal-title":"Pharmazie"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0022-510X(02)00047-3","volume":"197","author":"Flechter S.","year":"2002","unstructured":"Flechter S.; Vardi J.; Pollak L.; Rabey J.M.; Comparison of glatiramer acetate (Copaxone) and interferon \u03b2-1b (Betaferon) in multiple sclerosis patients: An open-label 2-year follow-up. J Neurol Sci  2002,197(1-2),51-55","journal-title":"J Neurol Sci"},{"year":"2023","unstructured":"SPC. Mavenclad.  Available from:  https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf2023","key":"ref=79"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","volume":"11","author":"Giovannoni G.","year":"2022","unstructured":"Giovannoni G.; Mathews J.; Cladribine tablets for relapsing\u2013remitting multiple sclerosis: A clinician\u2019s review. Neurol Ther  2022,11(2),571-595","journal-title":"Neurol Ther"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501272301231124074141","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/224043\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501272301231124074141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T09:11:08Z","timestamp":1706865068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/224043\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":80,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501272301231124074141","relation":{},"ISSN":["1389-4501"],"issn-type":[{"type":"print","value":"1389-4501"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}